FDAsafety guidance72% confidence
Real-World Evidence Submissions to the Center for Drug Evaluation and Research
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Biogen.
Regulatory Analysis
As part of the reauthorization of the Prescription Drug User Fee Act (PDUFA VII), FDA committed to reporting aggregate and anonymized information on submissions.
Supporting Context
- Therapeutic area
- Neurology · Amyotrophic Lateral Sclerosis
- Sub-indication
- General
Related signal: Analysis Reveals Key Trends in ALS Immunotherapeutics Research and Collaboration Gaps